• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Amgen

Amgen

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Data From Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Statin Intolerant Patients And In Patients On ...

    Data From Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Statin Intolerant Patients And In Patients On Statins

  2. New Detailed Data from Three Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medicine Evolocumab Significantly Reduced LDL Cholesterol By 55-66 Percent Compared To ...

    New Detailed Data from Three Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medicine Evolocumab Significantly Reduced LDL Cholesterol By 55-66 Percent Compared To Placebo In Patients With High Cholesterol

  3. 4 Harmful Market Myths

    This article represents opinions of the author and not those of his firm and are subject to change from time to time and do not constitute a recommendation to purchase and sale any security nor to engage in any particular investment strategy. The information contained here has been obtained from ...

  4. Phase 3 Pivotal Data On Amgen's Novel Investigational Cholesterol-Lowering Medicine To Be Featured At The American College of Cardiology's 63rd Annual Scientific Session

    Phase 3 Pivotal Data On Amgen's Novel Investigational Cholesterol-Lowering Medicine To Be Featured At The American College of Cardiology's 63rd Annual Scientific Session

  5. The Deal Announces Candidates For Seventh Annual Most Admired Corporate Dealmakers Awards

    The Deal Announces Candidates For Seventh Annual Most Admired Corporate Dealmakers Awards

  6. Riding the Tech Roller Coaster

    Riding the Tech Roller Coaster

  7. Medalist Funds Like These Large-Cap Stocks

    We crunch the numbers to see which stocks are most widely held among analyst-recommended large-cap funds.

  8. Credit Market Outlook: Bonds Priced for the Benign

    Corporate credit spreads are fairly valued--albeit at the tight end of the range that we view as fairly valued.

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.